NVCR Insider Trading
Insider Ownership Percentage: 6.29%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $61,749.10
NovoCure Share Price & Price History
Current Price: $18.47
Price Change: ▲ Price Increase of +0.155 (0.85%)
As of 04/29/2025 03:03 PM ET
NovoCure Insider Trading History
NovoCure Institutional Trading History
Data available starting January 2016
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More on NovoCure
Today's Range
Now: $18.47
52 Week Range
Now: $18.47
Volume
229,420 shs
Average Volume
1,182,013 shs
Market Capitalization
$2.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.65
Who are the company insiders with the largest holdings of NovoCure?
NovoCure's top insider investors include:
- Wilhelmus Cm Groenhuysen (COO)
- Ashley Cordova (CFO)
- W Anthony Vernon (Director)
- Frank X Leonard (EVP)
- Pritesh Shah (Insider)
- Michal Nath Puri (Insider)
- Mukund Paravasthu (COO)
Learn More about top insider investors at NovoCure.
Who are the major institutional investors of NovoCure?
NovoCure's top institutional shareholders include:
- Bank of New York Mellon Corp — 0.29%
- Rhumbline Advisers — 0.14%
- Taylor Frigon Capital Management LLC — 0.11%
- Teacher Retirement System of Texas — 0.06%
- Summit Trail Advisors LLC — 0.05%
- GAMMA Investing LLC — 0.05%
Learn More about top institutional investors of NovoCure stock.
Which major investors are selling NovoCure stock?
In the last quarter, NVCR stock was sold by these institutional investors:
- Taylor Frigon Capital Management LLC
Within the last year, company insiders that have sold NovoCure company stock include:
- Wilhelmus Cm Groenhuysen (COO)
- Ashley Cordova (CFO)
- W Anthony Vernon (Director)
- Frank X Leonard (EVP)
- Pritesh Shah (Insider)
Learn More investors selling NovoCure stock.
Which major investors are buying NovoCure stock?
In the last quarter, NVCR stock was acquired by institutional investors including:
- GAMMA Investing LLC
- Summit Trail Advisors LLC
- SG Americas Securities LLC
- Simon Quick Advisors LLC
- Kera Capital Partners Inc.
- Versant Capital Management Inc
- Exchange Traded Concepts LLC
- Wealthquest Corp